No evidence-based drug policy
24 items
1 source
Failure to mandate that independent evaluation findings deterministically guide the future of safe drug consumption facilities.
Cross-Source Insight
No evidence-based drug policy has been flagged across 1 independent accountability source:
24 PFD reports
This theme has been identified in one data source. As more data is added, cross-references may emerge.
PFD Reports (24)
Stella LeClaire
Concerns: The rising number of deaths from a substance sold for suicide raises concerns, emphasizing the need for routine toxicological analysis to improve evidence for potential prosecutions against suppliers.
Overdue
Joshua Leatham-Prosser
Concerns: Ketamine is easily accessible, perceived as less harmful by teenagers, and its highly addictive nature causes severe, irreversible bladder damage (ketamine cystitis), trapping users in a cycle of dependence.
Responded
Edward Barnard
Concerns: A vulnerable young adult illicitly obtained an animal-licensed substance for suicide, highlighting an emerging risk. Licensing bodies and veterinary societies must examine preventive measures to curb access and prevent future deaths.
Overdue
Hannah Aitken
Concerns: The increasing use of for self-harm is not centrally monitored, and current legislation fails to control the import and availability of substances used for poisoning, despite known risks.
Responded
James Boland
Concerns: Ketamine's Class B classification falsely portrays it as safer than Class A drugs, encouraging illicit use despite causing severe, life-changing health problems like urological and liver damage.
Responded
Louise Jones
Concerns: The GP practice lacked a treatment strategy and policies for long-term opioid prescriptions, including warning flags for addiction risk and guidance on co-prescribing opioids with benzodiazepines.
Responded
Sean Crawford
Concerns: There is a critical lack of specific medical and official guidance regarding the fatal risks associated with combining clozapine with alcohol.
Responded
Glenn Lockwood
Concerns: Insufficient monitoring for Pregabalin abuse in a patient with a known drug abuse history was identified, and the review of record-keeping and prescribing issues for the drug was found to be inadequate.
Responded
Frances Newbury
Concerns: Paramedics failed to administer Naloxone despite a patient's reported illicit drug use and clear physical signs. This highlights a missed opportunity for potentially life-saving intervention in opiate overdose cases.
Responded
Victoria Storey
Concerns: A highly potent, illicitly traded synthetic opiate with high fatal overdose risk is not yet controlled as a Class A, Schedule 1 drug, despite official advice for its urgent inclusion.
Overdue
Raymond Lee
Concerns: Limited national guidance and evidence exist for treating oesophageal strictures, particularly regarding the optimal number of dilatations versus stenting and associated perforation risks.
Responded
Sienna Barber
Concerns: Lack of national guidance for diagnosing and treating Group A Streptococcus, particularly for high-risk groups like children under 5, and the absence of rapid antigen testing for under 5s, creates diagnostic delays.
Responded
Chester Mossop
Concerns: Bath seats create a false sense of security for parents, despite not being safety devices. There is a concerning lack of national advice to healthcare professionals and parents regarding their safe use.
Responded
Kayleigh Burns
Concerns: The legal framework concerning Nitrous Oxide needs review due to increasing use by young persons and its association with deaths.
Overdue
James Lacey
Concerns: Harmful substances are easily purchased with less rigorous control than 'regulated poisons,' lacking restrictions like licensing and record-keeping, posing a risk of misuse.
Overdue
Samuel Morgan
Concerns: Patient information leaflets for SSRIs lack immediate, high-impact warnings, such as a "Black Box Warning," to clearly highlight the increased risk of suicidal thinking in young adults.
Responded
Marc Cole
Concerns: There is insufficient independent data and understanding regarding the lethality and incremental risks of multiple Taser activations, potentially leading to deficient police training and unsafe use.
Responded
Alexander Boamah
Concerns: A lack of process for clinicians to alert DWP about vulnerable individuals receiving large funds, particularly those without capacity, puts them at high risk of illicit substance misuse.
Responded
Mohammed Ahmed
Concerns: Combined use of Olanzapine and Spice caused a fatal allergic reaction, yet Olanzapine continued to be prescribed. Clinicians may lack national awareness of serious drug interactions and side effects with Olanzapine.
Overdue
Bethany Shipsey
Concerns: The highly toxic and antidote-less drug DNP is readily available online and popular as a 'diet drug.' There is a lack of legislation making its possession or supply illegal.
Responded
Howard Jeffers
Concerns: The inability to accurately analyze and detect novel psychoactive substances (NPS) through toxicological testing poses an ongoing risk of future deaths.
Responded
Anthony Garrett
Concerns: Readily available and misused synthetic cannabinoids, despite warnings, are dangerous and caused a fatal cardiac event. Concerns were raised about their legal status and control.
Overdue
Matthew Flatman
Concerns: The slow process of proscribing the "legal high" MDAI/Gogaine poses a fatal risk, particularly to users with cardiac problems, requiring accelerated action.
Overdue
Bradley Cockel
Concerns: The drug involved, and several of its chemical compounds, were not fully controlled by legislation, leading to regulatory gaps and potential public health risks.
Pending